Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tetsushu Onita has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimized Flomoxef Dosing Strategy for Extended-Spectrum Beta-Lactamase-Producing Bacteria, Based on Pooled Pharmacokinetic and Pharmacodynamic Analysis

    byĀ Tetsushu Onita, Yui Sano, Nami Kuruma, Kazuro Ikawa, Noriyuki Ishihara, Hiroki Tamaki, Kenta Yagi, Takahisa Yano

    Background: Flomoxef exhibits antibacterial activity against extended-spectrum beta-lactamase (ESBL)-producing bacteria and is a potential alternative to carbapenems. However, its pharmacokinetic (PK) characteristics remain unclear, and the appropriate minimum inhibitory concentration (MIC) breakpoint for flomoxef remains controversial. This study aimed to develop a flomoxef PK model using pooled meta-analysis and to evaluate various dosing regimens for ESBL-producing bacterial infections. Methods: Flomoxef concentration data were systematically collected from PubMed and J-STAGE. PK modeling of flomoxef was performed using the collected serum concentration data with NONMEM 7.5. Patient characteristics were examined as covariates for clearance and volume of distribution. For stochastic PK/pharmacodynamic (PD) simulation, the probability of attaining the PK/PD target {70% free time above the MIC [fT > MIC]} was calculated. The target MIC was determined by systematically reviewing flomoxef susceptibility data for ESBL-producing bacteria across different regions. Results: The population PK analysis included 39 adult patients [mean age, 58.2 years; mean body weight, 52.7 kg; and mean creatinine clearance (CLcr), 44.1 mL/min]. In the PK model, CLcr was incorporated as a covariate of flomoxef clearance. A visual predictive check and goodness-of-fit plots demonstrated relatively good stability and predictive performance of the final model. For the PD evaluation, the target MIC was set at 4 µg/mL based on the systematically collected susceptibility data for ESBL-producing bacteria. PK/PD breakpoints for dosing regimens of 1 g twice daily (2 g/day) in typical patients with CLcr = 10 mL/min, 1 g three times daily (3 g/day) in patients with CLcr = 30 mL/min, and 1 g four times daily (4 g/day) with 3 h-infusion in patients with CLcr = 60 and 90 mL/min achieved the target MIC. Conclusions: Based on the stochastic PK/PD simulation results, prolonged-infusion regimens may more effectively cover isolates with a target MIC of 4 µg/mL than short-duration infusion regimens in typical patients with normal renal function (CLcr = 60 or 90 mL/min). However, clinical studies in various scenarios including severe infections are needed to identify the relationship between PK/PD results and clinical efficacy since our findings are based solely on simulation.

  • Open Access

    Cerebrospinal Pharmacokinetic and Pharmacodynamic Evaluation of Sulbactam: Dosing Considerations for Acinetobacter baumannii Meningitis in Pediatric Patients

    byĀ Tetsushu Onita, Kazuro Ikawa

    Background: Effective sulbactam dosing regimens for treating Acinetobacter baumannii meningitis in pediatric patients, considering the degree of cerebrospinal fluid (CSF) inflammation and its consequent effect on drug penetration, have not been thoroughly studied. This study aimed to describe a cerebrospinal pharmacokinetic (PK) model of sulbactam and propose a dosing strategy in pediatric patients based on pharmacodynamic (PD) evaluation with stochastic simulation. Methods: Publications were systematically extracted from MEDLINE for sulbactam CSF PK data collection. A cerebrospinal PK model was described using CSF samples and applied to estimate the probability of attaining the PK/PD target (60% time above the minimum inhibitory concentration [T > MIC] in CSF). The cerebrospinal PK/PD breakpoint was defined as the highest MIC at which the target attainment probability in CSF was ≄90% for each age group (infants [4 weeks to 11 months], children [1-6 years], and pediatrics [7-16 years]). Results and Discussion: The study population included 21 pediatric patients aged 0.083-13.5 years. The CSF/serum concentration ratio at the various sampling points ranged 0.002-0.695. Based on the result of covariate analysis, CSF protein and CSF glucose levels were incorporated into the CSF-to-serum partition coefficient. The visual predictive check of CSF concentrations indicated no major bias. Regarding the cerebrospinal PK/PD evaluation, in infants and children groups with meningeal inflammation (eg, CSF protein > 100 mg/dL and CSF glucose < 40 mg/dL) a sulbactam dose of 200 mg/kg/day (as sulbactam component) with 0.5-h infusion was required to achieve 90% probability of CSF target attainment (60% T > MIC) up to an MIC of 4 μg/mL for A. baumanii. Conclusions: This study identified effective dosing regimens for A. baumannii meningitis in pediatric patients in consideration of the degree of inflammation in CSF. High-dose sulbactam regimens can be considered to optimize CSF target attainment for A. baumannii meningitis in pediatric patients.


  • Open Access

    Cerebrospinal Pharmacokinetic Modeling and Pharmacodynamic Simulation of High-Dose Cefazolin for Meningitis Caused by Methicillin-Susceptible Staphylococcus aureus

    byĀ Tetsushu Onita, Kazuro Ikawa, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano

    Background: Cefazolin is being increasingly used to treat central nervous system infections caused by methicillin-susceptible Staphylococcus aureus (MSSA) to mitigate the side effects of existing anti-Staphylococcal drugs. This study aims to develop a cerebrospinal pharmacokinetic (PK) model to predict the cefazolin concentration in cerebrospinal fluid (CSF) and to individualize the dosing regimen for MSSA meningitis. Methods: A cerebrospinal PK model was developed based on the existing literature and used to estimate the probability of attaining PK/ pharmacodynamic (PD) targets. These targets were set as 100% time above the minimum inhibitory concentration (T > MIC) in CSF. The cerebrospinal PK/PD breakpoint was defined as the highest MIC at which target attainment probability in CSF was ≄90%. The mean CSF/serum ratio estimated from the literature was 0.0525 after a dose of 1–3 g (sampling time: 1–9 h after dose) in adult patients with suspected meningitis. This ratio was incorporated into this PK model based on a hybrid approach. Results: For patients with creatinine clearance (CLcr) = 90 mL/min, the cerebrospinal PK/PD breakpoint MICs of continuous infusion regimens (6–12 g/day) reached 0.5 µg/mL, which can inhibit the growth of 90% of the MSSA population (MIC90). Furthermore, for patients with renal dysfunction (CLcr = 30 mL/min), a dose reduction (4 g/day) may be required to avoid excessive drug exposure. Conclusions: High-dose continuous infusion of cefazolin may be appropriate for MSSA meningitis in patients with normal renal function, while dose adjustments are needed for those with renal impairment.


  • Open Access

    Population Pharmacokinetic Analysis and Pharmacodynamic Evaluation of Sulbactam in Pediatric Patients: Dosing Suggestions for Acinetobacter baumannii Infections

    byĀ Tetsushu Onita, Yui Sano, Kazuro Ikawa, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano

    Background: This study aims to develop a population pharmacokinetic (PK) model of sulbactam in pediatric patients using pooled data analysis, and to optimize dosing regimens against Acinetobacter baumannii infections. Methods: Publications were systematically identified with MEDLINE for collecting sulbactam PK data in pediatric patients. Sulbactam PK model was developed using plasma concentration–time data gained from identified literature works. Based on the model, we estimated the probability of attaining the pharmacodynamic (PD) target against A. baumannii. Results: The data were adequately described by 2-compartment model. Age was a statistically significant covariate in clearance. Aiming for the PD target of 60% of time above minimum inhibitory concentration in free drug concentrations (fT > MIC), the breakpoint MICs were increased by extending infusion time from 0.5 to 4 hours. The breakpoint MICs for 4-hour infusion regimens of 25 mg/kg 4 times daily (100 mg/kg/day) achieved 4 μg/mL in infants (4 weeks to 11 months), children (1–6 years old) and pediatrics (7–16 years old). The breakpoint values for 4-hour infusions of 50 mg/kg 4 times daily (200 mg/kg/day) achieved 8 μg/mL (intermediate range of Clinical and Laboratory Standards Institute criteria) in all age groups. Conclusions: This population PK analysis and PD evaluation suggest that higher dosing regimen, especially with extended infusion time, should be reasonable for treating A. baumannii infections in pediatric patients.


  • Population Pharmacokinetic Analysis of Cefoperazone-Sulbactam in Pediatric Patients: Simultaneous Analysis of Plasma and Urine Data for Optimal Dosing Regimens

    byĀ Tetsushu Onita, Yui Bpharm Sano, Kazuro Ikawa, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano

    Background: This study aimed to develop population pharmacokinetic (PK) models of cefoperazone and sulbactam through simultaneous analysis of plasma and urine data in pediatric patients and to optimize dosing regimens based on PK/pharmacodynamic (PD) simulation. Methods: Population PK models of cefoperazone and sulbactam were separately developed by simultaneously fitting plasma and urine data from pediatric patients described in 9 published articles. Probabilities of attaining the bactericidal target of 70% of free time above minimum inhibitory concentration (70% fT > MIC) for cefoperazone against clinical isolates of common bacteria were estimated based on the final model. Results: Seventy-eight pediatric patients were the subjects for PK modeling (0.83–14.6 years old and 6–51.6 kg of body weight). A total of 439 plasma concentrations and 138 urinary excretions up to 7 hours after administration were used for population PK modeling. The data were adequately described by 2-compartment models for cefoperazone and sulbactam. Age was not a statistically significant covariate in the PK of both drugs. For empiric therapy of community-acquired pneumonia, the PK/PD breakpoint of 0.5-hour infusion of 20 mg/kg (cefoperazone-sulbactam dose ratio of 1:1) 4 times daily was 0.13 μg/mL and could cover MIC90 of Streptococcus pneumoniae (MIC90 = 0.125 μg/mL) and Haemophilus influenzae (MIC90 = 0.125 μg/mL). However, since MIC90 values for nosocomial pathogens are high (MIC90 = 2 μg/mL for Staphylococcus aureus and MIC90 = 4 μg/mL for Morganella morganii), a 4-hour infusion of 60 mg/kg (cefoperazone-sulbactam dose ratio of 2:1) 4 times daily might be better to cover many pathogens. Conclusions: This study described population PK models of cefoperazone and sulbactam detailing the excretion process with urine data in pediatric patients and developed optimal dosing regimens of cefoperazone-sulbactam including extended infusion in consideration with pathogens, based on PK/PD simulation.


  • Open Access

    PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance

    byĀ Tetsushu Onita, Noriyuki Ishihara, Takahisa Yano

    Antimicrobial resistance (AMR) poses a critical global health threat, necessitating the optimal use of existing antibiotics. Pharmacokinetic/pharmacodynamic (PK/PD) principles provide a scientific framework for optimizing antimicrobial therapy, particularly to respond to evolving resistance patterns. This review examines PK/PD strategies for antimicrobial dosing optimization, focusing on three key aspects. First, we discuss the importance of drug concentration management for enhancing efficacy while preventing toxicity, considering various patient populations, including pediatric and elderly patients with their unique physiological characteristics. Second, we analyze different PK modeling approaches: the classic top-down approach exemplified by population PK analysis, the bottom-up approach represented by physiologically based PK modeling, and hybrid models combining both approaches for enhanced predictive performance. Third, we explore clinical applications, including nomogram-based dosing strategies, Bayesian estimation, and emerging artificial intelligence applications, for real-time dose optimization. Critical challenges in implementing PK/PD simulation are addressed, particularly the selection of appropriate PK models, the optimization of PK/PD indices, and considerations concerning antimicrobial concentrations at infection sites. Understanding these principles and challenges is crucial for optimizing antimicrobial therapy and combating AMR through improved dosing strategies.


  • Open Access

    Antimicrobial Dosing Individualization Based on Pharmacokinetic/Pharmacodynamic Evaluation, Considering Factors of ā€œPatientā€, ā€œSite of infectionā€ and ā€œMicroorganismā€

    byĀ Tetsushu Onita

    The pharmacokinetic (PK)/pharmacodynamic (PD) approach has been widely used in clinical practice to optimize antimicrobial treatment. To promote the appropriate use of antimicrobial agents, it is important to consider certain factors, such as patient (e.g., age, physique, medical history, comorbidities, and organ dysfunction), site of infection (the target site where many causative bacteria are present), and microorganism (causative bacteria and susceptibility), and the dosing regimen should be selected based on the PK/PD approach. However, for renally excreted antibiotics, dosing regimens based on only renal function, such as creatinine clearance, are mainly used. Therefore, other factors such as patient pathological factors, antibiotic penetration of target sites, susceptibility of the causative bacteria to antibiotic, and clinical evaluation (efficacy and toxicity) should be considered simultaneously. These studies aimed to tailor the dosing of antimicrobial agents to individual patients by considering these factors. Multifaceted PK/PD evaluation may improve antimicrobial efficacy and safety, thereby contributing to the successful treatment of infectious diseases. Furthermore, improved treatment success rates may help manage the prevalence of antimicrobial-resistant bacteria, which is expected to become a significant problem in the future.

  • Prostatic Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime: Dosing Strategy for Bacterial Prostatitis

    byĀ Tetsushu Onita, Kogenta Nakamura, Genya Nishikawa, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano, Kohji Naora, Norifumi Morikawa, Kazuro Ikawa

    This study aimed to develop a prostatic pharmacokinetic model of ceftazidime and suggest more effective dosing strategy for the bacterial prostatitis, based on a site‐specific pharmacokinetic and pharmacodynamic perspective. Subjects were prostatic hyperplasia patients prophylactically receiving a 0.5‐h infusion of 1.0 g or 2.0 g ceftazidime before transurethral resection of the prostate. Plasma and prostate samples were premeditatedly collected after the administration and the concentrations were measured by high‐performance liquid chromatography. The prostate tissue/plasma ratio in area under the drug concentration‐time curve was approximately 0.476. The prostatic population pharmacokinetic model incorporated creatinine clearance (CLcr) into ceftazidime clearance was developed, and adequately predicted prostate tissue concentrations by diagnostic scatter plots and visual predictive checks. Aiming for a bactericidal target of 70% of time above minimum inhibitory concentration (T > MIC) in prostate tissue, 2.0 g twice daily achieved ≄90% expected probability against main pathogens like Escherichia coli and Proteus species in patients regardless of renal function (CLcr = 60 and 90 mL/min). However, since the expected probability of attaining the bactericidal target of 0.5‐h infusion dosing regimen did not achieve 90% against Pseudomonas aeruginosa in patients with CLcr = 60 and 90 mL/min, 4‐h infusion dosing regimen of 2.0 g three times daily (6 g/day) might be required for empirical treatment. Based on site‐specific simulations, the present study provides more effective dosing strategy for bacterial prostatitis.


  • Open Access

    Cerebrospinal Pharmacokinetic Analysis and Pharmacodynamic Evaluation of Ceftriaxone in Pediatric Patients with Bacterial Meningitis

    byĀ Tetsushu Onita, Kazuro Ikawa, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano, Norifumi Morikawa, Kohji Naora

    What Is Known? and Objective. Ceftriaxone has been widely used to treat bacterial meningitis in pediatric patients. Ceftriaxone dosing regimens of 80–120 mg/kg/day have been recommended for bacterial meningitis in pediatric patients, and the usual duration of therapy is 7–14 days. Although the target site for meningitis is cerebrospinal fluid (CSF), a CSF pharmacokinetic (PK) model in pediatric patients has not been reported. We aimed to develop a CSF PK model of ceftriaxone, using not only serum but also CSF concentration data, and to evaluate the appropriateness of dosing regimens for pediatric patients with bacterial meningitis. Methods. The population PK model was developed by simultaneously fitting serum and CSF data from pediatric patients described in nine published articles. Probabilities of attaining a pharmacodynamic target (100% T > MIC, 100% of time that drug concentrations above the minimum inhibitory concentration) in CSF were estimated for some dosing regimens. Results and Discussion. Twenty‐four pediatric patients with meningitis were the subjects for PK modeling (0.52–13 years old, and 3.5–50 kg of body weight). Sixty‐eight serum concentrations and 98 CSF samples were used to develop the CSF PK model. The CSF/serum concentration ratio at the same sampling time was 0.0628 ± 0.0689. Age was not a statistically significant covariate in the PK parameter. In the CSF PK model, 40–60 mg/kg q12 h achieved a target attainment probability >90% against causative bacteria for bacterial meningitis. However, 4‐h infusion (rather than 0.5‐h infusion) dosing regimens were required for efficacy against antimicrobial‐resistant bacteria with high MICs. What Is New? and Conclusion. Ceftriaxone‐dosing regimens with prolonged infusion times might be reasonably effective for treating antimicrobial‐resistant pathogens in empiric therapy.